常规外照射联合立体定向轻量GTV同步加量治疗疼痛性骨转移的HYBRID研究方案
HYBRID是一项前瞻性、多中心、跨国、单臂研究,计划入组100例实体瘤疼痛性骨转移成人患者,评估在常规外照射基础上对大体肿瘤体积(GTV)行「立体定向轻量」同步加量的可行性与安全性。主要终点为可行性(≥80%患者在CT模拟定位后10个工作日内开始放疗)与安全性(3个月内CTCAE v5.0≥2级急性毒性发生率),次要终点包括疼痛反应、局部无进展生存、椎体压缩骨折与长骨骨折、骨相关事件、生活质量及总生存。
要点
- 常规外照射同步加量方案为20 Gy/5次加5 Gy(共25 Gy)或30 Gy/10次加6 Gy(共36 Gy)。
- 主要终点为10个工作日内启动放疗比例≥80%及3个月内≥2级急性毒性。
- 该方案旨在兼顾姑息时效与局部控制,弥合常规外照射与SBRT之间的差距。
核心结论
- 在常规外照射基础上对GTV行同步「立体定向轻量」加量,可能成为兼顾局部控制与症状缓解的可行且安全的策略,尚待本研究验证。
研究设计与样本
- 前瞻性、多中心、跨国、单臂研究方案,计划入组100例实体瘤所致疼痛性骨转移成人患者。
- 放疗采用调强放疗或容积旋转调强放疗实施。
主要发现
- 骨转移致显著疼痛与功能受限,常规外照射可有效缓解症状但局部进展常见。
- SBRT局部控制更优,但常资源消耗大且椎体压缩骨折(VCF)发生率更高。
关键数值与推荐
- 方案A:20 Gy分5次,GTV加量5 Gy,总量25 Gy;方案B:30 Gy分10次,加量6 Gy,总量36 Gy。
- 可行性主要终点:CT模拟定位后10个工作日内开始放疗的患者比例≥80%。
- 安全性主要终点:3个月内CTCAE v5.0≥2级急性毒性发生率。
临床怎么用
- 可用于评估疼痛性骨转移患者在不延迟姑息治疗前提下接受同步加量的可行性,并监测急性毒性与骨折等事件。
局限性
- 为单臂研究方案,无同期对照,可行性与安全性为主要终点,疗效终点为次要观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bone metastases cause significant pain and functional limitation. Conventional external beam radiotherapy (EBRT) provides effective symptom relief, but local progression remains frequent. Stereotactic body radiotherapy (SBRT) offers improved local control but is often resource-intensive and associated with higher vertebral compression fracture (VCF) rates. Integrating a simultaneous gross tumour volume (GTV) boost within a conventional EBRT regimen may provide a feasible and safe alternative. METHODS: This is a prospective, multicentre, multinational, single-arm study enrolling 100 adults with painful bone metastases from solid tumours. Eligible patients receive 20 Gy in 5 fractions with a 5 Gy "stereotactic-lite" GTV boost (total 25 Gy) or 30 Gy in 10 fractions with a 6 Gy boost (total 36 Gy), delivered using intensity modulated radiotherapy or volumetric modulated arc therapy. The primary endpoints are feasibility (commencement of radiotherapy within 10 working days of computed tomography simulation in at least 80% of patients) and safety (incidence of Common Terminology Criteria for Adverse Events version 5.0 grade ≥ 2 acute toxicity within 3 months). Secondary endpoints include pain response, radiation site-specific progression-free survival, rates of VCF and long bone fracture, skeletal-related events, quality of life changes via EORTC QLQ-C30 and BM22, and overall survival. DISCUSSION: This protocol evaluates a hybrid EBRT approach with a simultaneous integrated boost as a practical strategy to enhance local tumour control and symptom relief without delaying palliation. If feasible and safe, this approach may bridge the gap between conventional EBRT and SBRT. TRIAL REGISTRATION: Australian and New Zealand Clinical Trial Registry (ACTRN12625000615482).
引用
- Lee SF, Choong ES, Leung J, et al. Study protocol: feasibility and safety of conventional external-beam radiotherapy with an integrated stereotactic lite gross-tumour-volume boost for painful bone metastases: the HYBRID study. Radiat Oncol. 2025. PMID: 41074082. doi:10.1186/s13014-025-02723-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。